|Symbols||; FLDB; LDLCQ4|
|External IDs||ChEMBL: GeneCards:|
|RNA expression pattern|
Apolipoprotein B (ApoB) are the primary apolipoproteins of chylomicrons and low-density lipoproteins (LDL - known commonly by the misnomer "bad cholesterol" when in reference to heart disease), which is responsible for carrying cholesterol to tissues. While it is unclear exactly what functional role ApoB plays in LDL, it is the primary apolipoprotein component and is absolutely required for its formation. What is clear is that the ApoB on the LDL particle acts as a ligand for LDL receptors in various cells throughout the body (i.e. less formally, ApoB "unlocks" the doors to cells and thereby delivers cholesterol to them). Through a mechanism that is not fully understood, high levels of ApoB can lead to plaques that cause vascular disease (atherosclerosis), leading to heart disease. There is considerable evidence that levels of ApoB are a better indicator of heart disease risk than total cholesterol or LDL. However, primarily for historic reasons, cholesterol, and more specifically, LDL-cholesterol, remains the primary lipid test for the risk factor of atherosclerosis.
- Genetic disorders 1
- Mouse studies 2
- Molecular biology 3
- Role in Innate Immune System 4
- Role in lipoproteins and atherosclerosis 5
- Role in longevity 6
- Interactions 7
- Interactive pathway map 8
- Regulation 9
RNA editing 10
- Type 10.1
- Location 10.2
- Regulation 10.3
- Conservation 10.4
- Structure 10.5.1
- Function 10.5.2
- See also 11
- References 12
- Further reading 13
- External links 14
High levels of ApoB are related to heart disease. Hypobetalipoproteinemia is a genetic disorder that can be caused by a mutation in the ApoB gene, APOB. Abetalipoproteinaemia is usually caused by a mutation in the MTP gene, MTP.
Mutations in gene APOB100 can also cause familial hypercholesterolemia, a hereditary (autosomal dominant) form of metabolic disorder Hypercholesterolemia.
Most relevant information regarding mouse ApoB homologue, mApoB, has come from mouse studies. Mice overexpressing mApoB have increased levels of LDL "bad cholesterol" and decreased levels of HDL "good cholesterol". Mice containing only one functional copy of the mApoB gene show the opposite effect, being resistant to hypercholesterolemia. Mice containing no functional copies of the gene are not viable.
The protein occurs in the plasma in 2 main isoforms, ApoB48 and ApoB100. The first is synthesized exclusively by the small intestine, the second by the liver. Both isoforms are coded by APOB and by a single mRNA transcript larger than 16 kb. ApoB48 is generated when a stop codon (UAA) at residue 2153 is created by RNA editing. There appears to be a trans-acting tissue-specific splicing gene that determines which isoform is ultimately produced. Alternatively, there is some evidence that a cis-acting element several thousand bp upstream determines which isoform is produced.
As a result of the RNA editing, ApoB48 and ApoB100 share a common N-terminal sequence, but ApoB48 lacks ApoB100's C-terminal LDL receptor binding region. In fact, ApoB48 is so called because it constitutes 48% of the sequence for ApoB100.
ApoB 48 is a unique protein to chylomicrons from the small intestine. After most of the lipids in the chylomicron have been absorbed, ApoB48 returns to the liver as part of the chylomicron remnant, where it is endocytosed and degraded.
Role in Innate Immune System
VLDL and LDL interfere with the quorum sensing system that upregulates genes required for invasive Staphylococcus aureus infection. The mechanism of antagonism entails binding ApoB, to a S. aureus autoinducer pheromone, preventing signaling through its receptor. Mice deficient in ApoB are more susceptible to invasive bacterial infection.
Role in lipoproteins and atherosclerosis
ApoB100 is found in lipoproteins originating from the liver (VLDL, IDL, LDL). Importantly, there is one ApoB100 molecule per hepatic-derived lipoprotein. Hence, using that fact, one can quantify the number of lipoprotein particles by noting the total ApoB100 concentration in the circulation. Since there is one and only one ApoB100 per particle, the number of particles is reflected by the ApoB100 concentration. The same technique can be applied to individual lipoprotein classes (e.g. LDL) and thereby enable one to count them as well.
It is well established that ApoB100 levels are associated with coronary heart disease, and are even a better predictor of it than is LDL level. A naive way of explaining this observation is to use the idea that ApoB100 reflects lipoprotein particle number (independent of their cholesterol content). In this way, one can infer that the number of ApoB100-containing lipoprotein particles is a determinant of atherosclerosis and heart disease.
One way to explain the above is to consider that large numbers of lipoprotein particles, and, in particular large numbers of LDL particles, lead to competition at the ApoB100 receptor (i.e. LDL receptor) of peripheral cells. Since such a competition will prolong the residence time of LDL particles in the circulation, it may lead to greater opportunity for them to undergo oxidation and/or other chemical modifications. Such modifications may lessen the particles' ability to be cleared by the classic LDL receptor and/or increase their ability to interact with so-called "scavenger" receptors. The net result is shunting of LDL particles to these scavenger receptors. Scavenger receptors typically are found on macrophages, with cholesterol laden macrophages being better known as "foam cells". Foam cells characterize atherosclerotic lesions. In addition to this possible mechanism of foam cell generation, an increase in the levels of chemically modified LDL particles may also lead to an increase in endothelial damage. This occurs as a result of modified-LDL's toxic effect on vascular endothelium as well its ability both to recruit immune effector cells and to promote platelet activation.
Recently, the INTERHEART study found that the ApoB100 / ApoA1 ratio is more effective at predicting heart attack risk, in patients who had had an acute myocardial infarction, than either the ApoB100 or ApoA1 measure alone. In the general population this remains unclear although in a recent study ApoB was the strongest risk marker for cardiovascular events. A small study suggests that added to fluvastatin treatment, omega 3 fatty acids daily, containing 460 mg of E-EPA and 380 mg of E-DHA (ethyl esters), may lower ApoB48 in hyperlipemic type 2 diabetics.
Role in longevity
In a 2014 study conducted at the Spanish National Cancer Research Center (CNIO), the human gene APOB (which encodes the production of ApoB) was identified as a potential longevity gene, based on a limited study of the exomes of seven exceptionally long-lived individuals (around 100 years old) from three families. APOB was the single rare functional variant (RFV) found in common between all members of the study. Though the results of this limited study did not reach statistical significance, it has demonstrated a trend that will be of interest for future research. APOB has previously been linked to hypobetalipoproteinemia, a sometimes considered to be "longevity syndrome".
ApoB has been shown to interact with apo(a), PPIB, Calcitonin receptor and HSP90B1. Interaction of ApoB with proteoglycans, collagen, and fibronectin is believed to cause atherosclerosis.
Interactive pathway map
Click on genes, proteins and metabolites below to link to respective articles. [§ 1]
- The interactive pathway map can be edited at WikiPathways: "Statin_Pathway_WP430".
The mRNA of this protein is subject to Cytidine to Uridine (C to U) site specific RNA editing. ApoB100 and ApoB48 are encoded by the same gene, however the differences in the translated proteins is not due to alternative splicing but is due to the tissue specific RNA editing event. ApoB mRNA editing was the first example of editing observed in vertebrates. Editing of ApoB mRNA occurs in all placental Mammals. Editing occurs post transcriptionally as the nascent polypeptides do not contain edited nucleosides.
C to U editing of ApoB mRNA requires an editing complex or holoenzyme (editosome) consisting of the C to U-editing enzyme Apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 (ApoBEC-1) as well as other auxiliary factors. ApoBEC-1 is a protein that in humans is encoded by the APOBEC1 gene.It is a member of the cytidine deaminase family. ApoBEC-1 alone is not sufficient for the editing of ApoB mRNA  and requires at least one of these auxiliary factors, APOBEC1 complementation factor (ACF) for editing to occur. ACF contains 3 non identical repeats. It acts as the RNA binding subunit and directs ApoBEC-1 to the ApoB mRNA downstream of the edited cytidine. Other auxiliary factors are known to be part of the holoenzyme. Some of these proteins have been identified. these are CUG binding protein 2 (CUGBP2), glycine-arginine-tyrosine-rich RNA binding protein (GRY-RBP), heterogenous nuclear ribonucleoprotein (hnRNP)-C1, ApoBEC-1 binding protein (ABBP)1, ABBP2, KH-type splicing regulatory binding protein (KSRP), Bcl-2-associated anthogene 4 (BAG4), and auxiliary factor (AUX)240. All these proteins have been identified using detection assays and have all been demonstrated to interact with either ApoBEC-1, ACF, or ApoB RNA. The function of these auxiliary proteins in the editing complex are unknown. As well as editing ApoB mRNA, the ApoBEC-1 editsome also edits the mRNA of NF1. mRNA editing of ApoB mRNA is the best defined example of this type of C to U RNA editing in humans.
Despite being a 14,000 residue long transcript, a single cytidine is targeted for editing. Within the ApoB mRNA a sequence consisting of 26 nucleotides necessary for editing is found. This is known as the editing motif. These nucleotides (6662–6687) were determined to be essential by site specific mutagenesis experiments. An 11 nucleotide portion of this sequence 4-5 nucleotides downstream from the editing site is an important region known as the mooring sequence. A region called the spacer element is found 2-8 nucleotides between the edited nucleoside and this mooring sequence. There is also a regulatory sequence 3' to the editing site. The active site of ApoBEC-1, the catalytic component of the editing holoenzyme is thought to bind to an AU rich region of the mooring sequence with the aid of ACF in binding the complex to the mRNA. The edited cytidine residue is located at nucleotide 6666 located in exon 26 of the gene. Editing at this site results in a codon change from a Glutamine codon (CAA) to an inframe stop codon (UAA). Computer modelling has detected for editing to occur,the edited Cytidine is located in a loop. The selection of the edited cytidine is also highly dependent on this secondary structure of the surrounding RNA. There are also some indications that this loop region is formed between the mooring sequence and the 3' regulatory region of the ApoB mRNA. The predicted secondary structure formed by ApoB mRNA is thought to allow for contact between the residue to be edited and the active site of APOBEC1 as well as for binding of ACF and other auxiliary factors associated with the editsome. Another
Editing of ApoB mRNA in humans is tissue regulated, with ApoB48 being the main ApoB protein of the small intestine in humans.It occurs in lesser amounts in the colon, kidney and stomach along with the non edited version. Editing is also developmentally regulated with the non edited version only being translated early in development but the edited form increases during development in the tissues where editing can occur. Editing levels of ApoB mRNA have been shown to vary in response to changes in diet. exposure to alcohol and hormone levels.
ApoB mRNA editing also occurs in mice, rats.In contrast to humans editing occurs in liver in mice and rats up to a frequency of 65%. It has not been observed in birds or lesser species.
Editing results in a codon change creating an in frame stop codon leading to translation of a truncated protein, ApoB48. This stop codon results in the translation of a protein which lacks the carboxyl terminus which contains the protein's LDLR binding domain. The full protein ApoB100 which has nearly 4500 amino acid is present in VLDL and LDL. Since many parts of ApoB100 are in amphipathic condition, the structure of some of its domains are dependent on underlying lipid condition. However it is known to have same over all folding in LDL having five main domains. Recently first structure of LDL at human body temperature in native condition has been found using cryo-electron microscopy at a resolution of 16 Angstrom. The overall folding of ApoB-100 has been confirmed and some heterogeneity in the local structure of its domains have been mapped.
Editing is restricted to those transcripts expressed in the small intestine. This shorter version of the protein has a function specific to the small intestine. The main function of the full length liver expressed ApoB100 is as ligand for activation of the LDL-R. However editing results in a protein lacking this LDL-R binding region of the protein. This alters the function of the protein and the shorter ApoB48 protein as specific functions relative to the small intestine. ApoB48 is identical to the amino terminal 48% of ApoB100. The function of this isoform is in fat absorption of the small intestine and is involved in the synthesis, assembly and secretion of chylomicrons. These chylomicrons transport dietary lipids to tissues while the remaining chylomicrons along with associated residual lipids are in 2–3 hours taken up by the liver via the interaction of apolipoprotein E (ApoE) with lipoprotein receptors. It is the dominant ApoB protein in the small intestine of most mammals. It is a key protein in the exogenous pathway of lipoprotein metabolism. Intestinal proteins containing ApoB48 are metabolised to chylomicron remnant particles which are taken up by remnant receptors.
- Contois JH, Warnick GR, Sniderman AD; Lee; Park; Jin; Jacobs Jr (2011). "Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement". Journal of Clinical Lipidology 5 (4): 264–272.
- Jacobson TA (2011). "Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk".
- Peterson MM, Mack JL, Hall PR, Alsup AA, Alexander SM, Sully EK, Sawires YS, Cheung AL, Otto M, Gresham HD.; Mack; Hall; Alsup; Alexander; Sully; Sawires; Cheung; Otto; Gresham (2008). "Apolipoprotein B is an innate barrier against invasive Staphylococcus aureus infection".
- MedlinePlus Encyclopedia Apolipoprotein B100
- McQueen MJ, Hawken S, Wang X et al. (July 2008). "Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study". Lancet 372 (9634): 224–33.
- Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A; Nordestgaard; Jensen; Tybjaerg-Hansen (2007). "Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study".
- Valdivielso P, Rioja J, García-Arias C, et al. (January 2009) "Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report." Cardiovasc Diabetol. 8:1. Free Full Text
- Cash, Timothy P.; Serrano, Manuel; Pita, Guillermo; Domínguez, Orlando; Alonso, Maria R.; Moreno, Leticia T. (12 August 2014). "Exome sequencing of three cases of familial exceptional longevity". Wiley. Aging Cell.
- Centro Nacional de Investigaciones Oncologicas (CNIO) (25 August 2014). "APOB, a gene involved in lipid transport, linked to cases of familial extreme longevity". ScienceDaily. Retrieved 6 September 2014.
- Malaguarnera M1, Vacante M, Russo C, Malaguarnera G, Antic T, Malaguarnera L, Bella R, Pennisi G, Galvano F, Frigiola A; Vacante; Russo; Malaguarnera; Antic; Malaguarnera; Bella; Pennisi; Galvano; Frigiola (2013). "Lipoprotein(a) in cardiovascular diseases". Biomed Research International 2013 (650989): 650989.
- Zhang, Jianying; Herscovitz Haya (Feb 2003). "Nascent lipidated apolipoprotein B is transported to the Golgi as an incompletely folded intermediate as probed by its association with network of endoplasmic reticulum molecular chaperones, GRP94, ERp72, BiP, calreticulin, and cyclophilin B". J. Biol. Chem. (United States) 278 (9): 7459–68.
- Linnik, K M; Herscovitz H (Aug 1998). "Multiple molecular chaperones interact with apolipoprotein B during its maturation. The network of endoplasmic reticulum-resident chaperones (ERp72, GRP94, calreticulin, and BiP) interacts with apolipoprotein b regardless of its lipidation state". J. Biol. Chem. (UNITED STATES) 273 (33): 21368–73.
- Khalil MF1, Wagner WD, Goldberg IJ; Wagner; Goldberg (2004). "Lipoprotein(a) in cardiovascular diseases".
- Tabas I1, Williams KJ, Borén J; Williams; Borén (2007). "Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications".
- Pontrelli, L; Sidiropoulos KG; Adeli K (2004). "Translational control of apolipoprotein B mRNA: regulation via cis elements in the 5' and 3' untranslated regions". Biochemistry 43 (21): 6734–6744.
- Powell LM, Wallis SC, Pease RJ, Edwards YH, Knott TJ, Scott J; Wallis; Pease; Edwards; Knott; Scott (September 1987). "A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine".
- Fujino T, Navaratnam N, Jarmuz A, von Haeseler A, Scott J; Navaratnam; Jarmuz; von Haeseler; Scott (July 1999). "C-->U editing of apolipoprotein B mRNA in marsupials: identification and characterisation of APOBEC-1 from the American opossum Monodelphus domestica".
- Lau PP, Xiong WJ, Zhu HJ, Chen SH, Chan L; Xiong; Zhu; Chen; Chan (October 1991). "Apolipoprotein B mRNA editing is an intranuclear event that occurs posttranscriptionally coincident with splicing and polyadenylation".
- Navaratnam N, Fujino T, Bayliss J et al. (January 1998). "Escherichia coli cytidine deaminase provides a molecular model for ApoB RNA editing and a mechanism for RNA substrate recognition".
- Blanc V, Kennedy S, Davidson NO; Kennedy; Davidson (October 2003). "A novel nuclear localization signal in the auxiliary domain of apobec-1 complementation factor regulates nucleocytoplasmic import and shuttling".
- Anant S, Henderson JO, Mukhopadhyay D et al. (December 2001). "Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing. CUGBP2 modulates C to U editing of apolipoprotein B mRNA by interacting with apobec-1 and ACF, the apobec-1 complementation factor".
- Blanc V, Navaratnam N, Henderson JO et al. (March 2001). "Identification of GRY-RBP as an apolipoprotein B RNA-binding protein that interacts with both apobec-1 and apobec-1 complementation factor to modulate C to U editing".
- Greeve J, Lellek H, Rautenberg P, Greten H; Lellek; Rautenberg; Greten (1998). "Inhibition of the apolipoprotein B mRNA editing enzyme-complex by hnRNP C1 protein and 40S hnRNP complexes".
- Lau PP, Villanueva H, Kobayashi K, Nakamuta M, Chang BH, Chan L; Villanueva; Kobayashi; Nakamuta; Chang; Chan (December 2001). "A DnaJ protein, apobec-1-binding protein-2, modulates apolipoprotein B mRNA editing".
- Lau PP, Chan L; Chan (December 2003). "Involvement of a chaperone regulator, Bcl2-associated athanogene-4, in apolipoprotein B mRNA editing".
- Schock D, Kuo SR, Steinburg MF et al. (February 1996). "An auxiliary factor containing a 240-kDa protein complex is involved in apolipoprotein B RNA editing".
- Davies MS, Wallis SC, Driscoll DM et al. (August 1989). "Sequence requirements for apolipoprotein B RNA editing in transfected rat hepatoma cells".
- Shah RR, Knott TJ, Legros JE, Navaratnam N, Greeve JC, Scott J; Knott; Legros; Navaratnam; Greeve; Scott (September 1991). "Sequence requirements for the editing of apolipoprotein B mRNA".
- Driscoll DM, Lakhe-Reddy S, Oleksa LM, Martinez D; Lakhe-Reddy; Oleksa; Martinez (December 1993). "Induction of RNA editing at heterologous sites by sequences in apolipoprotein B mRNA".
- Greeve J, Navaratnam N, Scott J; Navaratnam; Scott (July 1991). "Characterization of the apolipoprotein B mRNA editing enzyme: no similarity to the proposed mechanism of RNA editing in kinetoplastid protozoa".
- Richardson N, Navaratnam N, Scott J; Navaratnam; Scott (November 1998). "Secondary structure for the apolipoprotein B mRNA editing site. Au-binding proteins interact with a stem loop".
- Teng B, Verp M, Salomon J, Davidson NO; Verp; Salomon; Davidson (November 1990). "Apolipoprotein B messenger RNA editing is developmentally regulated and widely expressed in human tissues".
- Wu JH, Semenkovich CF, Chen SH, Li WH, Chan L; Semenkovich; Chen; Li; Chan (July 1990). "Apolipoprotein B mRNA editing. Validation of a sensitive assay and developmental biology of RNA editing in the rat".
- Glickman RM, Rogers M, Glickman JN; Rogers; Glickman (July 1986). "Apolipoprotein B synthesis by human liver and intestine in vitro".
- Baum CL, Teng BB, Davidson NO; Teng; Davidson (November 1990). "Apolipoprotein B messenger RNA editing in the rat liver. Modulation by fasting and refeeding a high carbohydrate diet".
- Lau PP, Cahill DJ, Zhu HJ, Chan L; Cahill; Zhu; Chan (October 1995). "Ethanol modulates apolipoprotein B mRNA editing in the rat".
- Chan L, Chang BH, Nakamuta M, Li WH, Smith LC; Chang; Nakamuta; Li; Smith (March 1997). "Apobec-1 and apolipoprotein B mRNA editing".
- Chan L (January 1993). "RNA editing: exploring one mode with apolipoprotein B mRNA".
- Tarugi P, Albertazzi L, Nicolini S, Calandra S; Albertazzi; Nicolini; Calandra (March 1990). "Absence of apolipoprotein B-48 in the chick, Gallus domesticus".
- Kumar V, Butcher SJ, Katrina O,Engelhardt P,Heikkonen J, Kaski K, Ala-Korpela M, Kovanen PT.; Butcher; Öörni; Engelhardt; Heikkonen; Kaski; Ala-Korpela; Kovanen (May 2011). Schulz, Christian, ed. "Three-Dimensional cryoEM Reconstruction of Native LDL Particles to 16Å Resolution at Physiological Body Temperature". PLoS ONE 6 (5): e18841.
- Knott TJ, Pease RJ, Powell LM et al. (1986). "Complete protein sequence and identification of structural domains of human apolipoprotein B".
- Mahley RW, Innerarity TL, Rall SC, Weisgraber KH; Innerarity; Rall Jr; Weisgraber (1985). "Plasma lipoproteins: apolipoprotein structure and function". J. Lipid Res. 25 (12): 1277–94.
- Itakura H, Matsumoto A; Matsumoto (1995). "[Apolipoprotein B]". Nippon Rinsho 52 (12): 3113–8.
- Chumakova OS, Zateĭshchikov DA, Sidorenko BA; Zateĭshchikov; Sidorenko (2006). "[Apolipoprotein B: structure, function, gene polymorphism, and relation to atherosclerosis]". Kardiologiia 45 (6): 43–55.
- Ye J (2007). "Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus". PLoS Pathog. 3 (8): e108.
- Database of RNA editing (DARNED).